Current news and events

Meeting in Oslo January 27-28, 2020:The Genetics and Genomics of Cancer

The Genetics and Genomics of Cancer meeting takes place at Holmenkollen Scandic Hotel January 27-28 2020. The meeting is organized by Oslo University Hospital, Faculty of Medicine at UiO, Akershus University Hospital,  Vestre Viken Hospital Trust and National Breast Cancer Network. More than 20 international speakers are confirmed.

National meeting about advanced molecular cancer diagnostics

Oncologist and pathologist from all the University Hospitals in Norway recently gather at the Norwegian Radium Hospital to discuss implementation of personalized medicine in cancer treatment.

The meeting was organized by the Division of Cancer Medicine at OUS to highlight the needs and challenges related to the advanced molecular diagnostics needed for implementation of personalized medicine in both clinic practice and clinical trials.

 

Article in Science from Kalager and Bretthauer:Improving cancer screening programs

Mette Kalager and Michael Bretthauer
Mette Kalager and Michael Bretthauer

National cancer screening programs are widely implemented to reduce cancer incidence and mortality in high-income countries, but there is insufficient knowledge of the utility and potential for harmful consequences of this practice. Several of the programs are introduced without the necessary testing of the methods in advance.
This is the topic of professor Mette Kalager and professor Michael Bretthauer's recent article in the prestigious journal Science.

Tuula Nyman awarded millions for scientific infrastructure for proteomics research

Tuula Nyman
Tuula Nyman

Tuula Nyman is awarded 57 million kroner for her project “National network for advanced proteomic-infrastructrure”, NAPI in short from the Norwegian Research Council.

Nyman is a researcher at the Department for immunology at the Institute of Clinical Medicine at UiO and Oslo University Hospital, and head of the Proteomics Core Facility.

Theodossiou interviewed for Smithsonian Magazine on how natural light may be used to kill cancer cells

Theodossis Theodossioiu
Theodossis Theodossioiu

Theodossis Theodossiou, senior researcher and leader of the Protonics project group at the Department of Radiation Biology, has recently been interviewed for the Smithsonian - the official journal published by the Smithsonian Institution in Washington, D.C.
His views on how natural light may be used in future cancer treatment are presented in a feature article entitled "How Studying Bioluminescent Creatures Is Transforming Medical Science".

Pierre Chymkowitch granted support from the FRIPRIO program

Pierre Chymkowitch
Pierre Chymkowitch

Dr. Pierre Chymkowitch from the Department of Microbiology at Oslo University Hospital has recently been granted 8.531 million NOK through the FRIPRO program from The Norwegian Research Council.

The “Researcher Project” receiving support is entitled “Regulation of mitotic transcription by centromeres”. 

Åslaug Helland principal investigator of large, randomized combination trial in mesothelioma

Åslaug Helland
Åslaug Helland

Ultimovacs ASA , a pharmaceutical company developing novel immunotherapies against cancer, announces that the universal cancer vaccine UV1 will be investigated in a randomized, multi-center phase II trial in mesothelioma.
Dr. Åslaug Helland, head of the Translational studies on solid tumours research group at the Department of Cancer Genetic, is principal investigator of the study.

Theodossis A. Theodossiou researcher of the year at the Institute for Cancer Research

Theodossiou with Institute head Kjetil Taskén during the ceremony
Theodossiou with Institute head Kjetil Taskén during the ceremony

Theodossis A. Theodossiou – senior researcher and project group leader at Institute for Cancer Research - was awarded the prize researcher-of-the-year 2019 from the leadership at ICR for his oustanding scientific contribution in 2019. The award of 100 000 NOK is financed by Radiumhospitalets legater and is a personal scholarship for stimulating further excellence in research. 


More news from the archive